Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

MGNX Stock - MacroGenics Stock Trading


home / stock / mgnx

MGNX MGNX Quote MGNX Short MGNX News MGNX Articles MGNX Message Board

MWN AI Summary *

MacroGenics Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics for the treatment of cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company employs a range of proprietary technologies, including monoclonal antibodies and antibody-drug conjugates, to create targeted therapies that aim to improve patient outcomes.

The company’s pipeline includes several candidates across various stages of clinical development. MacroGenics is particularly noted for its lead product candidate, Margetuximab, a monoclonal antibody designed to enhance the immune-mediated activity of other therapies. Margetuximab is being investigated in clinical trials for the treatment of HER2-positive cancers, including breast and gastric cancers. The drug is being evaluated both as a monotherapy and in combination with other agents, demonstrating MacroGenics' strategy to position its therapies in combination regimens for better efficacy.

In addition to Margetuximab, the company's pipeline includes several other promising candidates, such as its Dual-Affinity Re-Targeting (DART) platform therapies and next-generation antibody-drug conjugates. These innovative approaches highlight the company's commitment to advancing cancer treatment through cutting-edge science.

The financial health of MacroGenics has generally reflected the funding requirements typical of clinical-stage biotech firms, characterized by periodic capital raises to support its development pipeline. The company has formed various collaborations to bolster its research and development efforts.

As of October 2023, MacroGenics remains focused on advancing its key assets through clinical trials, emphasizing collaboration with industry partners, and looking to potentially capitalize on emerging market opportunities. Investors and analysts closely monitor MacroGenics for updates on clinical trial progress and regulatory developments, given the high stakes typical in the biopharmaceutical space.

MWN AI Analysis *

As of October 2023, MacroGenics Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company, is focused on developing innovative monoclonal antibodies for targeted therapies in cancer and autoimmune diseases. Investors should consider several key factors before making decisions on MGNX stock.

Firstly, the company has made significant strides in its clinical programs, particularly with MGD019, a dual-action bispecific T-cell engager aimed at treating various cancers. Positive clinical trial results can lead to heightened investor interest and potential stock price appreciation. Therefore, keeping an eye on upcoming clinical data releases and milestones is crucial for assessing the investment's potential.

Additionally, MacroGenics has partnered with larger pharmaceutical firms, which not only aids in funding its research but also provides validation of its technological platforms. Partnerships can also lead to shared resources, further enhancing the likelihood of successful product development. Monitoring news on partnerships and collaborations will be vital as they directly impact the company’s financial health and prospects.

From a financial perspective, while MacroGenics has a promising pipeline, the company has also faced challenges, including volatility in stock performance typical of biotech firms. Investors should evaluate the company’s burn rate and runway, given that clinical-stage companies often require substantial capital. Reviewing quarterly earnings reports will provide insights into cash reserves and funding strategies.

Lastly, the broader market environment for biotech companies will affect MGNX’s stock performance. Regulatory changes, economic conditions, and investor sentiment can all significantly influence market performance. As the industry adapts to evolving healthcare policies and economic factors, it's essential to assess how these macroeconomic trends could impact MacroGenics.

In conclusion, while MacroGenics presents an intriguing investment opportunity with a strong pipeline and partnerships, potential investors should conduct thorough due diligence, especially considering the inherent volatility and risks associated with biotech investments.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | MacroGenics Inc. (NASDAQ:MGNX)

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Quote | MacroGenics Inc. (NASDAQ:MGNX)

Last:$1.32
Change Percent: -3.65%
Open:$1.39
Close:$1.37
High:$1.4
Low:$1.31
Volume:211,680
Last Trade Date Time:06/20/2025 11:45:15 am

News | MacroGenics Inc. (NASDAQ:MGNX)

  • MacroGenics: Working On That Road To Recovery

    2025-06-11 18:32:08 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: MacroGenics: Working On That Road To Recovery

    • June 11, 2025 06:32:08 pm

    • |
    • SeekingAlpha
    • |
      • MGNX Stock
      • MGNX Quote
      • MGNX Short
      • MGNX News
      • MGNX Articles
      • MGNX Message Board
  • MacroGenics signs financial deal with Sagard for retifanlimab

    2025-06-10 11:05:01 ET More on MacroGenics, Incyte Incyte: Good Company, But Potentially Overvalued Given Patent Cliffs Incyte Corporation 2025 Q1 - Results - Earnings Call Presentation Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript Incyte rises a...

    • June 10, 2025 11:05:01 am

    • |
    • SeekingAlpha
    • |
      • MGNX Stock
      • MGNX Quote
      • MGNX Short
      • MGNX News
      • MGNX Articles
      • MGNX Message Board

Message Board Posts | MacroGenics Inc. (NASDAQ:MGNX)

Subject By Source When
whytestocks: $MGNX News Article - Why Shares of MacroGenics Climbed Thursday whytestocks investorshangout 03/16/2023 4:35:50 PM
Historic short interest: XenaLives investorshub 01/31/2023 7:02:57 PM
So what exactly did $MGNX do to this XenaLives investorshub 12/15/2022 12:42:06 AM
Looking at $MGNX because the chart is intriguing.. XenaLives investorshub 12/15/2022 12:38:51 AM
Now I need to figure out what DART XenaLives investorshub 12/15/2022 12:35:41 AM

MWN AI FAQ **

What recent clinical trial results have impacted the stock performance of MacroGenics Inc. (NASDAQ: MGNX) and what implications do they have for future growth?

Recent clinical trial results for MacroGenics Inc.'s MGD024, showing promising efficacy in treating acute myeloid leukemia, have led to a boost in stock performance and suggest potential for significant future growth in the oncology market.

How is MacroGenics Inc. (NASDAQ: MGNX) positioned in the competitive landscape of immuno-oncology therapies?

MacroGenics Inc. (NASDAQ: MGNX) is strategically positioned in the immuno-oncology landscape with its innovative pipeline of engineered monoclonal antibodies and compelling partnerships, although it faces competition from larger biotech firms with established treatments.

What potential partnerships or collaborations could enhance the pipeline and market reach of MacroGenics Inc. (NASDAQ: MGNX)?

Potential partnerships with larger biopharmaceutical companies for co-development or strategic alliances in immunotherapy and targeted therapies could enhance MacroGenics Inc.'s pipeline and market reach, leveraging shared resources and expertise to accelerate drug development and commercialization.

How has the financial health and funding strategy of MacroGenics Inc. (NASDAQ: MGNX) evolved amidst industry challenges?

MacroGenics Inc. has adapted its funding strategy to focus on strategic partnerships and collaborations while navigating industry challenges, enhancing its financial health through targeted investments and efforts to streamline operations amid shifting market dynamics.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get MGNX Alerts

News, Short Squeeze, Breakout and More Instantly...

MacroGenics Inc. Company Name:

MGNX Stock Symbol:

NASDAQ Market:

-3.65% G/L:

$1.32 Last:

211,680 Volume:

$1.39 Open:

$1.37 Close:

MacroGenics Inc. Website:

MacroGenics Inc. Logo

Ad

Investor Relations
RECENT MGNX NEWS
  • MGNX - MacroGenics Receives $70M from Sagard Healthcare Partners in Royalty Agreement for ZYNYZ

    2025-06-10 07:37:10 ET Extends Cash Runway Through 1H 2027 DENVER, Colo., Jun 10, 2025 ( 247marketnews.com )- MacroGenics (NASDAQ:MGNX) entered into a royalty purchase agreement with Sagard Healthcare Partners , in which MacroGenics received a $70 million upfront cash ...

  • MGNX - MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025

    ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company...

  • MGNX - Expected US Company Earnings on Tuesday, May 13th, 2025

    urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get MGNX Alerts

Get MGNX Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1